The thesis

Eli Lilly is a leading global pharmaceutical firm with significant exposure to GLP-1 and metabolic health. The company reported 47.7% year-over-year revenue growth, driven by its Zepbound and Mounjaro products. With a conviction score of 37/100, it is on the WATCHLIST. Gross margin is 8401.0% and net margin is 3353.0%, indicating high profitability.

Why now

US Zepbound revenue grew 122% year-over-year in Q4 2025, indicating strong demand for Eli Lilly's GLP-1 drugs. The current macro context, with risk_on_rotation inactive, may impact investor sentiment towards the company.

What to watch

Investors should monitor Eli Lilly's revenue growth trajectory and competitive pipeline developments over the next 1-3 quarters. Key metrics to watch include future quarterly revenue growth rates and any updates on the company's product pipeline.

Key risks

Valuation risk is high with a P/E ratio of 38.4x and competitive pipeline risk from other pharmaceutical companies developing similar GLP-1 drugs. Execution risk is also present as the company needs to continue delivering strong revenue growth.

Theme exposure